Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Eur Rev Med Pharmacol Sci ; 26(21): 8030-8038, 2022 11.
Article in English | MEDLINE | ID: mdl-36394754

ABSTRACT

OBJECTIVE: Adrenergic receptors belong to the G protein-coupled receptor family and are one of the important targets of modern drug therapy. Dexmedetomidine (DEX) is a highly selective agonist of alpha2 receptor, a member of the adrenergic receptor family, which are widely found in immune tissues and which mediate the biological behaviour of the inflammatory immune system. This review mainly summarizes the role of DEX in immune tissue and inflammation-related diseases, to provide a theoretical basis for clinical treatment. MATERIALS AND METHODS: We searched the PUBMED, EMBASE, and Cochrane libraries separately to obtain published literature on DEX related to immune tissue and inflammatory diseases. The mesh (dexmedetomidine replaces DEX, microglia, astrocytes, spleen, marrow, lymph nodes) and their corresponding keywords used for the searches, and no time limit for retrieval. The latest search was conducted on July 1, 2022. RESULTS: By reading a lot of relevant literature, we found that DEX reduces the inflammatory response of brain tissue by interfering with microglia and astrocytes. DEX can regulate the expression of CD40 and CD86 markers on the surface of splenocytes and reduce the secretion of inflammatory cytokines by splenocytes. In addition, we found that DEX reduced inflammation-related diseases such as neuroinflammation, myocarditis, liver cirrhosis, osteoarthritis, upper respiratory tract infection, pancreatitis, spinal tuberculosis, pulpitis, colon inflammation and rheumatoid arthritis, and improved prognosis. CONCLUSIONS: DEX has anti-inflammatory and improved prognosis in many inflammatory related diseases and is expected to become a targeted drug for the treatment of inflammatory diseases.


Subject(s)
Dexmedetomidine , Humans , Dexmedetomidine/pharmacology , Dexmedetomidine/therapeutic use , Microglia/metabolism , Cytokines/metabolism , Anti-Inflammatory Agents/therapeutic use , Inflammation/drug therapy , Inflammation/metabolism
2.
Eur J Surg Oncol ; 43(10): 1855-1861, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28756019

ABSTRACT

BACKGROUND: Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with "weak" estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%-20%, and ER or PR >20% by hormone therapy. METHODS: Medical records of 3353 breast cancer patients treated from 2006 to 2013 were retrospectively reviewed. Tumor characteristics, type of treatment, OS, DFS and DSS were evaluated among the three patient groups. RESULTS: Regarding OS, there were significant differences according to the received hormone therapy in the different groups: ER and PR <1% (P = 0.972), ER and PR 1%-20% (P = 0.264), and ER or PR >20% (P = 0.014). Regarding DFS and DSS, there were also significant differences in the different groups: ER and PR <1% (P = 0.611, 0.766), ER and PR 1%-20% (P = 0.847, 0.629), and ER or PR >20% (P = 0.031, 0.002). CONCLUSIONS: In HER2 negative breast cancer patient with hormone therapy, ER and PR expression level of 1%-20% has similar survival outcome to the ER and PR expression level of <1% by IHC analysis.


Subject(s)
Receptor, ErbB-2/metabolism , Receptors, Estrogen/biosynthesis , Receptors, Progesterone/biosynthesis , Triple Negative Breast Neoplasms/mortality , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Disease-Free Survival , Female , Follow-Up Studies , Hormone Replacement Therapy/methods , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Middle Aged , Retrospective Studies , Survival Rate/trends , Taiwan/epidemiology , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/metabolism , Young Adult
3.
Article in Chinese | MEDLINE | ID: mdl-29294516

ABSTRACT

Objective: To investigate the dynamic expression of placenta growth factor (PlGF) in the lungs and its role in paraquat-induced pulmonary fibrosis and to evaluate the effect of ACEI captopril and AT (1) -receptor blocker losartan on paraquat-induced pulmonary fibrosis. Methods: 84 adult healthy female Sprague-Dawley (SD) rats were randomly divided into four groups of different treatments designated as: Control, PQ alone (PQ) , captopril treatment, losartan treatment. Each group was divided into three subgroups of seven animals each. The animals were killed at either 7, 14 or 28 days after PQ administration. The rats in PQ group, treatment group were treated intragastrically (ig) with PQ (40 mg/kg) and the rats in control group were treated with the same dose of saline at the beginning of the experiment. The treatment group received Captopril (60 mg/kg; ig) or Losartan (10 mg/kg; ig) once a day respectively after PQ administration and the other two groups received saline. At the given timepoint, animals were sacrificed and lungs were harvested. A semiquantitative assay of histological examination, hydroxyproline in lung tissues were used to determine the severity of alveolitis and fibrosis. RT-PCR and immunohistochemistry were used to detect the mRNA and protein expression of PlGF. Results: Inflammatory cell infiltration and fibrotic scores were more prominent in the model group, hydroxyproline contents in lung tissue were significantly increased after PQ administration compared to the control group. Captopril, losartan apparently attenuated the degree of lung injury and pulmonary fibrosis. On 7th, 14th days, the levels of alveolitis in the intervention groups were significantly alleviated as compared with the model group (P<0.05) . On 28th days, the levels of pulmonary fibrosis in the intervention groups were significantly alleviated as compared with model group (P<0.05) . The hydroxyproline contents in the intervention groups were significantly decreased as compared with model group (P<0.01) . PlGF mRNA on day 7, 14, 28 (1.28±0.29vs0.10±0.01、0.80±0.07vs0.10±0.01、0.65±0.13vs0.10±0.01) in the PQ group were all upregulated as compared with that of the control group. PlGF mRNA on day 7, 14, 28 in the captopril and Losartan intervention groups were significantly decreased (0.94±0.04、0.71±0.09、0.52±0.24 and 0.80±0.12、0.66±0.11、0.51±0.03) . PlGF positive expression index on day 7, 14, 28 (2.27±0.34 vs0.13±0.01、1.78±0.41 vs0.14±0.03、1.25±0.69 vs0.13±0.01) in the PQ group were all upregulated as compared with that of the control group. PlGF positive expression index on day 7, 14, 28 in the captopril and Losartan treatment groups were significantly decreased (1.53±0.78、1.17±0.79、0.97±0.61 and 1.36±0.63、1.24±0.80、0.83±0.47) . PlGF positive expression index on day 7 in the two intervention groups were significantly decreased, as compared with PQ group (P<0.05) . Conclusion: PlGF may plays an important role in the development of pulmonary fibrosis following paraquat-induced lung injury in rats. Captopril and losartan had an inhibitory effect on paraquat-induced pulmonary fibrosis, and the effect may be due to inhibition of angiotensin II and, in part, be associated with reduction in PlGF.


Subject(s)
Captopril/pharmacology , Losartan/pharmacology , Paraquat/toxicity , Placenta Growth Factor/metabolism , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/drug therapy , Animals , Female , Lung/metabolism , Lung/pathology , Placenta Growth Factor/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley
4.
Oncogene ; 34(13): 1688-97, 2015 Mar 26.
Article in English | MEDLINE | ID: mdl-24769896

ABSTRACT

Upregulated expression of nucleolar GTPase nucleostemin (NS) has been associated with increased cellular proliferation potential and tumor malignancy during cancer development. Recent reports attribute the growth regulatory effects of NS protein to its role in facilitating ribosome production. However, the oncogenic potential of NS remains unclear, as imbalanced levels of NS have been reported to exert growth inhibitory effect by modulating p53 tumor-suppressor activity. It also remains in questions if aberrant NS levels might have a p53-independent role in regulation of cell proliferation and growth. In this study, we performed affinity purification and mass spectrometry analysis to explore protein-protein interactions influencing NS growth regulatory properties independently of p53 tumor suppressor. We identified the alternative reading frame (ARF) protein as a key protein associating with NS and further verified the interaction through in vitro and in vivo assays. We demonstrated that NS is able to regulate cell cycle progression by regulating the stability of the ARF tumor suppressor. Furthermore, overexpression of NS suppressed ARF polyubiquitination by its E3 ligase Ubiquitin Ligase for ARF and elongated its half-life, whereas knockdown of NS led to the decrease of ARF levels. Also, we found that NS can enhance NPM stabilization of ARF. Thus, we propose that in the absence of p53, ARF can be stabilized by NS and nucleophosmin to serve as an alternative tumor-suppressor surveillance, preventing potential cellular transformation resulting from the growth-inducing effects of NS overexpression.


Subject(s)
Carrier Proteins/antagonists & inhibitors , GTP-Binding Proteins/physiology , Nuclear Proteins/physiology , Tumor Suppressor Protein p14ARF/physiology , Ubiquitin-Protein Ligases/antagonists & inhibitors , Cell Line, Tumor , G1 Phase Cell Cycle Checkpoints , GTP-Binding Proteins/chemistry , Humans , Nuclear Proteins/chemistry , Protein Stability , Protein Structure, Tertiary , Proto-Oncogene Proteins c-mdm2/physiology , Tumor Suppressor Protein p14ARF/chemistry , Tumor Suppressor Protein p53/physiology
7.
Ann Oncol ; 22(5): 1170-1180, 2011 May.
Article in English | MEDLINE | ID: mdl-21115603

ABSTRACT

BACKGROUND: Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined. METHODS: We completed a comprehensive literature search of all published rituximab-associated HBV-R cases and from the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) MedWatch database. Literature and FDA cases were compared for completeness, and a meta-analysis was completed. RESULTS: One hundred and eighty-three unique cases of rituximab-associated HBV-R were identified from the literature (n = 27 case reports, n = 156 case series). The time from last rituximab to reactivation was 3 months (range 0-12), although 29% occurred >6 months after last rituximab. Within FDA data (n = 118 cases), there was a strong signal for rituximab-associated HBV-R [proportional reporting ratio = 28.5, 95% confidence interval (CI) 23.9-34.1; Empiric Bayes Geometric Mean = 26.4, 95% CI 21.4-31.1]. However, the completeness of data in FDA reports was significantly inferior compared with literature cases (P < 0.0001). Among HBV core antibody (HBcAb(+)) series, the pooled effect of rituximab-based therapy showed a significantly increased risk of HBV-R compared with nonrituximab-treated patients (odds ratio 5.73, 95% CI 2.01-16.33; Z = 3.33, P = 0.0009) without heterogeneity (χ(2) = 2.12, P = 0.5473). CONCLUSIONS: The FDA AERS provided strong HBV-R safety signals; however, literature-based cases provided a significantly more complete description. Furthermore, meta-analysis of HBcAb(+) series identified a more than fivefold increased rate of rituximab-associated HBV-R.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/adverse effects , Antineoplastic Agents/adverse effects , Hepatitis B virus , Hepatitis B/chemically induced , Lymphoproliferative Disorders/drug therapy , Adult , Adverse Drug Reaction Reporting Systems , Aged , Aged, 80 and over , Female , Hepatitis B/complications , Humans , Lymphoproliferative Disorders/complications , Lymphoproliferative Disorders/virology , Male , Middle Aged , Recurrence , Rituximab , United States , United States Food and Drug Administration , Young Adult
9.
Liver Int ; 24(6): 540-6, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15566502

ABSTRACT

BACKGROUND: Recent data suggest that hepatitis B virus (HBV) reactivation develops in 41% of breast cancer (BC) patients carrying HBV after chemotherapy. Our study aimed to determine the role of preemptive use of lamivudine in BC patients undergoing chemotherapy. PATIENTS AND METHODS: The test group consisted of 11 female patients with BC who were seropositive for hepatitis B surface antigen (HBsAg). Of these, 10 patients were treated in an adjuvant setting and one for metastatic disease. Lamivudine was given from the start of chemotherapy and was maintained until 1 month after the last infusion of chemotherapy. The control group consisted of nine historical BC patients carrying HBV and received similar systemic chemotherapy without preemptive lamivudine. Variables including HBsAg, HBV envelope antigen, anti-HBV envelope antibody, serial serum alanine transaminase (ALT), quantitative HBV viral DNA analysis, and HBV-DNA precore promoter and precore sequence were monitored. Test for emergence of mutant strains, notably nucleotide 550, was performed 6 months after the completion of chemotherapy. RESULTS: All patients tolerated lamivudine well without development of evident HBV reactivation or overt hepatitis. Serum ALT remained unchanged without rebound hepatitis after cessation of chemotherapy and withdrawal of lamivudine. No emergence of lamivudine-selective resistant strain (so-called tyrosine-methionine-aspartate-aspartate mutations) was observed. CONCLUSIONS: Our results encourage preemptive use of lamivudine for prevention of HBV reactivation in patients who need short-term chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Hepatitis B virus/isolation & purification , Hepatitis B/prevention & control , Lamivudine/administration & dosage , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Base Sequence , Breast Neoplasms/pathology , Breast Neoplasms/virology , DNA, Viral/analysis , Female , Follow-Up Studies , Hepatitis B/drug therapy , Hepatitis B Surface Antigens/analysis , Humans , Middle Aged , Molecular Sequence Data , Monitoring, Physiologic , Primary Prevention/methods , Prospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Risk Assessment , Secondary Prevention , Serologic Tests , Treatment Outcome
10.
Eur J Neurol ; 11(7): 493-6, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15257690

ABSTRACT

Malignancy-related thromboembolism, so-called Trousseau's syndrome, can present as acute cerebral infarction, non-bacterial thrombotic endocarditis (NBTE) and migratory thrombophlebitis. It is usually attributed to a cancer-related hypercoagulable state, chronic disseminated intravascular coagulopathy (DIC), or tumour embolism. We report on two patients with adenocarcinoma of the colon and cholangiocarcinoma who developed widespread thromboembolism during disease progression. Both did poorly despite aggressive institution of anticoagulation therapy. These cases emphasize that cerebral infarction or refractory thromboembolism in cancer-treated patients should prompt investigation for recurrent or metastatic disease or progression of the underlying malignancy. Optimal treatment remains to be established.


Subject(s)
Adenocarcinoma/complications , Bile Duct Neoplasms/complications , Bile Ducts, Intrahepatic , Cholangiocarcinoma/complications , Colonic Neoplasms/complications , Intracranial Embolism/etiology , Adult , Female , Humans , Intracranial Embolism/pathology , Magnetic Resonance Imaging , Middle Aged , Tomography, X-Ray Computed
11.
J Viral Hepat ; 11(3): 283-5, 2004 May.
Article in English | MEDLINE | ID: mdl-15117333

ABSTRACT

We recently treated a patient with severe aplastic anaemia (SAA) who also had chronic hepatitis B virus (HBV) infection. The HBV serological status at the time of diagnosis of SAA was HBsAg(+) and HBeAg(+). Subsequent analysis of the precore region of HBV DNA showed wild-type. He received anti-thymocyte globulin (ATG) and cyclosporin A (CsA) therapy twice. After each course of ATG infusion and during CsA therapy he developed lymphopenia for 1 and 2.5 months, respectively. His serum alanine aminotransferase (ALT) became normalized during the period of lymphopenia, but the serum HBV viral load increased. When his peripheral lymphocytes count recovered, his ALT became elevated again. Lamivudine was effective to normalize his elevated ALT and suppress viral replication. The phenomenon observed in this case supports the prevailing notion that hepatitis B flare-up in HBV carriers after chemotherapy is caused by an immune-mediated mechanism. Meanwhile, this is the first documented case of SAA who developed HBV reactivation upon recovery of lymphopenia after immunosuppressive therapy. This also highlights the necessity of pre-emptive therapy with lamivudine in SAA/HBsAg(+) patients to receive immunosuppressive therapy with ATG/CsA.


Subject(s)
Anemia, Aplastic/complications , Anemia, Aplastic/drug therapy , Hepatitis B, Chronic/complications , Immunosuppressive Agents/therapeutic use , Adult , Anemia, Aplastic/immunology , Antilymphocyte Serum/adverse effects , Antilymphocyte Serum/therapeutic use , Antiviral Agents/therapeutic use , Carrier State/drug therapy , Carrier State/immunology , Cyclosporine/adverse effects , Cyclosporine/therapeutic use , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/immunology , Humans , Immunosuppressive Agents/adverse effects , Lamivudine/therapeutic use , Male , Recurrence
12.
Ann Hematol ; 82(10): 646-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12879283

ABSTRACT

We describe an 82-year-old man with undiagnosed chronic lymphocytic leukemia (CLL) who presented with acute swelling of the thyroid goiter. Subsequent thyroid aspirate and blood culture yielded group B Salmonella thyroid abscess with septicemia. Infectious complications are the major cause of morbidity and mortality in patients with CLL since most of them can be timely detected and few can arise from innocent-looking lesions.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/complications , Salmonella Infections/pathology , Salmonella typhimurium , Thyroiditis, Suppurative/microbiology , Thyroiditis, Suppurative/pathology , Abscess/complications , Aged , Aged, 80 and over , Humans , Male , Salmonella Infections/complications , Thyroiditis, Suppurative/diagnosis , Tomography, X-Ray Computed
13.
Ann Hematol ; 82(8): 518-520, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12838369

ABSTRACT

A 34-year-old man was diagnosed as having solitary testicular plasmacytoma. He had received palliative radiotherapy, several combined chemotherapies including CHOP chemotherapy (vincristine, cyclophosphamide, Adriamycin, and prednisone), MP (melphalan and prednisone) and M-2 protocol (melphalan, prednisone, vincristine, carmustine, and cyclophosphamide), and interferon therapy as 3 million units subcutaneous injection three times a week for 1 year. Extensive bone plasmacytoma developed 7 years later without bone marrow involvement. We suggest that early use of combined chemoradiotherapy and high-dose chemotherapy with autologous stem cell support should be investigated in patients with testicular plasmacytoma with dissemination.


Subject(s)
Plasmacytoma/secondary , Skull Neoplasms/metabolism , Skull Neoplasms/pathology , Testicular Neoplasms/pathology , Adult , Antineoplastic Agents, Alkylating/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow/pathology , Carmustine/therapeutic use , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Humans , Male , Melphalan/therapeutic use , Plasma Cells/pathology , Plasmacytoma/drug therapy , Plasmacytoma/radiotherapy , Plasmacytoma/surgery , Prednisone/therapeutic use , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/radiotherapy , Testicular Neoplasms/drug therapy , Testicular Neoplasms/surgery , Tomography, X-Ray Computed , Vincristine/therapeutic use
14.
Ann Hematol ; 82(7): 452-4, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12750843

ABSTRACT

Pyomyositis is a rare complication of chemotherapy. A 35-year-old male patient with myelodysplastic syndrome developed Stenotrophomonas maltophilia bacteremia shortly after chemotherapy, and Stenotrophomonas maltophilia-related pyomyositis was encountered after recovery from neutropenia. He recovered completely after surgical drainage and a protracted course of antibiotic treatment. It is postulated that subclinical myopathy, immunosuppression secondary to the malignancy, or chemotherapeutic drugs may predispose to pyomyositis. Early recognition of this unusual complication in a cancer patient undergoing chemotherapy can prevent further catastrophes.


Subject(s)
Antineoplastic Agents/adverse effects , Myositis/chemically induced , Sepsis/chemically induced , Stenotrophomonas maltophilia , Adult , Diagnosis, Differential , Humans , Leg/pathology , Magnetic Resonance Imaging , Male , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/drug therapy , Myositis/diagnosis , Myositis/therapy , Opportunistic Infections , Sepsis/diagnosis , Sepsis/therapy
15.
Clin Nephrol ; 59(3): 201-5, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12653264

ABSTRACT

Tumor lysis syndrome (TLS) is a well recognized complication of chemotherapy and radiotherapy for leukemia, lymphoma as well as rapidly growing malignancies. Less described is the occurrence of TLS following steroid therapy alone. Herein, we report on a 32-year-old male with myelodysplastic syndrome, characterized by refractory anemia with excess blasts in transformation, who developed acute oliguric renal failure 12 hours after methylprednisolone 1.0 g for presumed autoimmune thrombocytopenia. Laboratory investigations revealed typical findings of TLS, including hyperkalemia, marked hyperuricemia, hyperphosphotemia, hypocalcemia and urine uric acid to creatinine ratio 1.8 (> 1.0). Long hemodialysis (8 hours) was initiated for 3 consecutive sessions. Renal function recovered 1 week later. This case high-lights that single-dose steroid administration in a patient with hematological malignancy may cause the potential life-threatening complications of TLS. Prophylactic management prior to the use of steroid therapy for a variety of purposes is absolutely required in high-risk patients.


Subject(s)
Acute Kidney Injury/chemically induced , Glucocorticoids/adverse effects , Methylprednisolone/adverse effects , Myelodysplastic Syndromes/complications , Tumor Lysis Syndrome/etiology , Adult , Humans , Male
16.
Cancer ; 92(11): 2927-32, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11753968

ABSTRACT

BACKGROUND: A point mutation from G to A at nucleotide (nt) 1896 of the precore region of hepatitis B virus (HBV) DNA has been shown to be associated with fulminant and severe hepatitis. Further studies have suggested that this point mutation, together with additional mutations in the precore promoter, is probably linked to the reactivation of HBV in patients undergoing cytotoxic chemotherapy. Taiwan is an area with a high prevalence of HBV where hepatitis B flare-up has become a serious problem of HBV carriers who must rely on chemotherapy to treat their diseases. The purpose of this study was to examine if nt 1896 mutation was also present in Chinese patients in Taiwan who developed severe liver disease after chemotherapy. MATERIALS AND METHODS. Thirteen HBV carrier patients, including eight patients with lymphoma, two with germ cell tumors, two with breast carcinomas, and one with acute myeloid leukemia, received chemotherapy in the authors' hospital from February 1994 to May 2000. They all received steroid-containing regimens or antiemetics during chemotherapy. These patients were monitored closely for the development of severe hepatitis during or after chemotherapy. Their sera were harvested at different times for direct sequencing of the polymerase chain reaction products of the precore region of HBV DNA. RESULTS: Six of the 13 patients developed severe hepatitis with a fulminant course during or after the completion of chemotherapy. A point mutation from G to A at nt 1896 was detected in five of these six patients. Among those five patients, four had additional precore mutations. The other patient did not have the nt 1896 mutation but had mutations at nt 1835 (A to C). None of the other seven patients lacking the precore nt 1896 mutation developed severe hepatitis flare-up. One of those seven patients who developed moderate elevation of alanine aminotransferase (ALT) without hyperbilirubinemia did have precore mutations other than nt 1896. None of the other six patients had mutations over the precore region. CONCLUSIONS: Nucleotide mutation of the precore region, notably at position 1896, is associated with reactivation of HBV with a fulminant course during or after chemotherapy. The current data, together with other investigators' findings, suggest that patients who are HBV carriers with HBV envelope antigen (HBeAg) (-)/anti-HBV envelope antibody (Anti-HBe)(+) status should be assayed to determine if they carry mutant HBV before chemotherapy. Prophylactic use of lamivudine is strongly recommended for patients who carry mutant HBV at precore region, especially at nt 1896 (G to A), before and during chemotherapy.


Subject(s)
Hepatitis B virus/genetics , Hepatitis B/virology , Virus Activation/genetics , Adult , Aged , Drug-Related Side Effects and Adverse Reactions , Female , Hepatitis B/epidemiology , Hepatitis B/etiology , Hepatitis B virus/drug effects , Hepatitis B virus/growth & development , Hepatitis B virus/physiology , Humans , Lymphoma/complications , Lymphoma/drug therapy , Male , Middle Aged , Mutation , Taiwan/epidemiology
17.
Am J Hematol ; 68(2): 87-90, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11559947

ABSTRACT

Pulmonary complications are frequently encountered in patients with hematological malignancy. The optimal therapeutic decision including open lung biopsy (OLB) for such patients is uncertain. We herein examine the clinical impact of OLB on these patients. Seven patients with progressively diffuse pulmonary infiltrates despite aggressive medical treatment were examined. The underlying diseases, prior treatment for presumptive pneumonia, the change in therapeutic approach after operation, and clinical outcome were reviewed retrospectively. Diffuse pulmonary infiltrates were caused by infection in two patients and by noninfectious etiology such as alveolar proteinosis, idiopathic interstitial pneumonitis, leukemic involvement, and drug-induced alveolar damage in the others. Four patients who had serious underlying hematologic diseases such as myelodysplastic syndrome, acute and chronic myeloid leukemia, and T cell lymphoma died. Three patients with acute lymphoid leukemia survived. In two of these three, change of therapeutic strategies after OLB was created for the survival. OLB in patients with hematological malignancy may be useful in selected patients with a treatable hematologic disease who have treatable underlying causes of the pulmonary infiltrate.


Subject(s)
Biopsy/methods , Hematologic Neoplasms/pathology , Lung Diseases/diagnosis , Lung/pathology , Adolescent , Adult , Cause of Death , Combined Modality Therapy , Female , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Humans , Lung/microbiology , Lung Diseases/drug therapy , Lung Diseases/etiology , Lung Diseases/pathology , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome
18.
Acta Cardiol ; 56(1): 37-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11315122

ABSTRACT

Acute aortic dissection may have variable presentations, making the diagnosis clinically challenging. Although fever is a common accompanying feature, it rarely dominates the clinical setting. We report the case of a patient who sustained a prolonged spiking fever with unknown origin following acute aortic dissection. The case serves as a reminder that prolonged fever may be the principal residual sequelae after acute aortic dissection or one of the protean clinical manifestations of painless aortic dissection.


Subject(s)
Aortic Aneurysm/complications , Aortic Dissection/complications , Fever of Unknown Origin/etiology , Female , Humans , Middle Aged
19.
J Hematother Stem Cell Res ; 9(5): 651-8, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11091489

ABSTRACT

Our previous study demonstrated that transduction of murine embryonic stem (ES) cells with a human erythropoietin (Epo) receptor (R) cDNA resulted in enhanced erythropoiesis in developing embryonic bodies (EBs). To address possible mechanisms of gene regulation, we compared gene expression between hEpoR cDNA-transduced ES (ES-hEpoR) cells and parental ES cells during in vitro differentiation induced by withdrawal of leukemia inhibitory factor (LIF) and cultured in the absence of Epo using differential display reverse transcriptase-polymerase chain reaction (DDRT-PCR). A total of 48 differentially expressed cDNA fragments were found; 12 were sequenced and five were confirmed by Northern blot analysis to be up- or down-regulated in ES-hEpoR cells during differentiation compared to parental ES cells. In a GenBank search of the five putatively regulated cDNA fragments, two fragments shared high sequence homology to two known genes: the Surf-6 gene and the gene for calcyclin binding protein. Northern blot analysis demonstrated that 2.5-kb and 0.3-kb transcripts of the Surf-6 gene were expressed in undifferentiated ES-hEpoR and parental ES cells at a low level, but this expression was enhanced from day 2 to 14 of differentiation after withdrawal of LIF and culture in the presence of Epo. Furthermore, the enhanced expression of these two transcripts was also noticed in EML-C1 cells, a murine multipotential hematopoietic cell line that has erythroid differentiation potential in response to Epo. In summary, our results demonstrate that Surf-6 gene expression is regulated during differentiation of hematopoietic stem/progenitor cells in response to Epo, suggesting a possible role for Surf-6 gene in erythropoiesis.


Subject(s)
Gene Expression Regulation/physiology , Receptors, Erythropoietin/physiology , Stem Cells/physiology , Animals , Blastocyst/cytology , Blastocyst/physiology , Cell Differentiation , DNA, Complementary , Gene Expression Profiling , Humans , Mice , Nuclear Proteins/genetics , Receptors, Erythropoietin/genetics , Recombinant Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Stem Cells/cytology
20.
Blood ; 96(12): 3985-7, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11090089

ABSTRACT

The dynamics of cell cycle regulation were investigated during in vitro erythroid proliferation and differentiation of CD34(+) cord blood cells. An unusual cell cycle profile with a majority of cells in S phase (70.2%) and minority of cells in G1 phase (27.4%) was observed in burst-forming unit-erythrocytes (BFU-E)-derived erythroblasts from a 7-day culture of CD34(+) cells stimulated with interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), Steel factor, and Epo. Terminal erythroid differentiation was accompanied by a rapid increase of G0/G1 phase cells. Expression of cyclin E and cyclin-dependent kinase 2 (cdk2) correlated with the proportion of S phase cells. Cyclin D3 was moderately up-regulated during the proliferation phase, and both cyclin E and D3 were rapidly down-regulated during terminal differentiation. This suggests that the high proliferation potential of erythroblasts is associated with temporal up-regulation of cyclin E and cdk2. (Blood. 2000;96:3985-3987)


Subject(s)
CDC2-CDC28 Kinases , Cell Cycle Proteins/metabolism , Hematopoietic Stem Cells/cytology , Cell Culture Techniques , Cell Cycle/drug effects , Cell Cycle/physiology , Cell Cycle Proteins/drug effects , Cell Cycle Proteins/physiology , Cell Differentiation/drug effects , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinases/metabolism , Cyclin-Dependent Kinases/physiology , Cyclins/drug effects , Cyclins/metabolism , Cyclins/physiology , Cytokines/pharmacology , Erythroid Precursor Cells/cytology , Fetal Blood/cytology , Hematopoietic Stem Cells/drug effects , Humans , Protein Serine-Threonine Kinases/metabolism , Protein Serine-Threonine Kinases/physiology , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...